PVH
NBIX icon

Psagot Value Holdings’s Neurocrine Biosciences NBIX Stock Holding History

Psagot Value Holdings’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-11
Closed -$1K – 376
2023
Q4 		$1K Sell
11
-11
-50% -$1.27K ﹤0.01% 505
2023
Q3 		$3K Sell
22
-8
-27% -$842 ﹤0.01% 420
2023
Q2 		$3K Buy
30
+4
+15% +$391 ﹤0.01% 399
2023
Q1 		$3K Buy
+26
New +$2.71K ﹤0.01% 379
2021
Q2 		– Sell
-205,473
Closed -$20M – 482
2021
Q1 		$20M Hold
205,473
– – 0.45% 62
2020
Q4 		$19.7M Buy
205,473
+69,464
+51% +$6.71M 0.46% 59
2020
Q3 		$13.1M Buy
+136,009
New +$15.7M 0.33% 73

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Psagot Value Holdings's NBIX Position: Q1 2024 in Review

Psagot Value Holdings sold out of Neurocrine Biosciences (NBIX) in Q1 2024, closing a stake of 11 shares — an estimated $1K sold.

Psagot Value Holdings first reported a position in NBIX in Q3 2020 and held it in 7 quarters. The position peaked at $20M in Q1 2021. 589 funds tracked by Wall St. Rank hold NBIX as of Q1 2024.

  • Psagot Value Holdings reported no remaining Neurocrine Biosciences position as of Q1 2024 after selling out during the quarter.
  • Psagot Value Holdings sold 11 Neurocrine Biosciences shares in Q1 2024, an estimated $1K.
  • Psagot Value Holdings first reported a position in Neurocrine Biosciences in Q3 2020 and held it in 7 quarters.
  • Psagot Value Holdings's Neurocrine Biosciences position peaked at $20M in Q1 2021.
  • 589 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2024.

Based on Psagot Value Holdings's 13F filing for Q1 2024, filed 15 May 2024.